HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

peptide NY-ESO-1 157-165

Also Known As:

NY-ESO-1 157-165 peptide

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Neoplasm Proteins: 2
    - peptide NY-ESO-1 157-165: 3
- Peptides: 82426
  - Peptide Fragments: 373
    - peptide NY-ESO-1 157-165: 3

Experts

1.	Ayyoub, Maha: 1 article (05/2005)
2.	Cerottini, Jean-Charles: 1 article (05/2005)
3.	Dietrich, Pierre-Yves: 1 article (05/2005)
4.	Dutoit, Valérie: 1 article (05/2005)
5.	Jäger, Elke: 1 article (05/2005)
6.	Le Gal, Frédérique-Anne: 1 article (05/2005)
7.	Valmori, Danila: 1 article (05/2005)
8.	Widmer, Valérie: 1 article (05/2005)
9.	Cerottini, J C: 1 article (03/2001)
10.	Dutoit, V: 1 article (03/2001)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 07/15/2000 - "NY-ESO-1 157-165 peptide analogues were compared for their antigenicity and immunogenicity using PBL from melanoma patients. " 03/01/2001 - "The results of this analysis revealed that, although suboptimal for binding to the HLA-A*0201 molecule, peptide NY-ESO-1 157-165 is, among natural sequences, very efficiently recognized by specific CTL clones derived from three melanoma patients. "
2.	Neoplasms (Cancer) 05/01/2005 - "In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epitope corresponding to peptide NY-ESO-1 157-165. "

Related Drugs and Biologics

1.	Immunodominant Epitopes
2.	HLA-A*02:01 antigen